Phase 1 Study of HBN-1

Summary

Phase 1 First-in Human randomized, open-label, active control standard of care study of the safety of HBN-1 administered as pharmacologically induced hypothermia as an adjunct to standard of care targeted temperature management in adult patients who have experienced out-of-hospital-cardiac arrest. HBN-1 will be administered IV as a loading dose infusion followed by a 12-hour maintenance infusion.

Timeline

Start

2019-10-30

Primary completion

2020-11-01

Completion

2020-12-31

Drugs

Indications